Login to Your Account

Titan Halts Phase II Studies Of Pivanex In NSCL Cancer

By Aaron Lorenzo

Tuesday, June 22, 2004
Safety concerns prompted Titan Pharmaceuticals Inc. to stop a year-old Phase IIb study of its cancer drug Pivanex. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription